Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is ...
Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the ...
Cencora has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.
Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.2% over the past month. The stock hit a new 52-week high of $262.56 in the previous session.
Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...
COR opened at $253.88 on Wednesday. The firm has a market cap of $49.23 billion, a P/E ratio of 36.11, a P/E/G ratio of 1.31 and a beta of 0.51. Cencora has a 12 month low of $214.77 and a 12 ...
With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions provider specializing in pharmaceutical distribution and related services.
Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to 5,599.30 and ...
Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline ...
Cencora (NYSE:COR – Get Free Report) had its price objective increased by analysts at Wells Fargo & Company from $251.00 to $274.00 in a report released on Friday,Benzinga reports.The firm ...
In a recent 8-K filing with the Securities and Exchange Commission, Cencora, Inc., a Delaware-based company in the wholesale drug industry and a prominent player in Healthcare Providers & Services ...